|
Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. |
|
|
Honoraria - Amgen; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides |
Consulting or Advisory Role - amgen; bms; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides |
Speakers' Bureau - amgen; celgene; Takeda |
Research Funding - amgen; bms; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics |
|
|
Stock and Other Ownership Interests - OncoPep |
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; BeiGene; Bristol-Myers Squibb; Celgene; Janssen; Karyopharm Therapeutics; Karyopharm Therapeutics; OncoPep; Takeda |
Patents, Royalties, Other Intellectual Property - Oncopep |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech/Abbvie; Indapta Therapeutics; Karyopharm Therapeutics; Oncopeptides; Precision Biosciences; Sanofi; Surface Oncology |
Research Funding - Bluebird Bio; Celgene; Janssen; Nektar; poseida therapeutics; Sutro biopharma; Teneobio |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Legend Biotech; Sanofi; Takeda |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen; Karyopharm Therapeutics; Legend Biotech |
|
|
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); crispr therapeutics (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Legend Biotech (Inst); Secura Bio (Inst); SERVIER (Inst); Takeda (Inst) |
Research Funding - Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Amgen (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celularity (Inst); Constellation Pharmaceuticals (Inst); crispr therapeutics (Inst); CURIS (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Glenmark (Inst); Ichnos Sciences (Inst); Janssen (Inst); Kesios Therapuetics (Inst); Lilly (Inst); Novartis (Inst); poseida therapeutics (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst); Vivolux (Inst) |
|
|
Stock and Other Ownership Interests - TG Therapeutics |
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Sanofi; Takeda |
Research Funding - Bristol-Myers Squibb; Celgene; Takeda |
Other Relationship - TG Therapeutics |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Merck; Novartis; Takeda |
Research Funding - Bluebird Bio (Inst) |
|
David Samuel DiCapua Siegel |
Honoraria - Amgen; Bristol-Myers Squibb; Celularity; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Merck; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celularity; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Merck; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Merck; Takeda |
Research Funding - Amgen; Bristol-Myers Squibb; Celularity; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Merck; Takeda |
|
|
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Sorrento Therapeutics (Inst); Vineti (Inst) |
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Amgen; Celgene; GlaxoSmithKline; Janssen; Sanofi |
Speakers' Bureau - Amgen; Celgene |
|
|
Honoraria - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; Sanofi |
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen; Sanofi |
|
|
Honoraria - Biotest; Celgene; Gilead Sciences; Janssen; Jazz Pharmaceuticals; Novartis |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Honoraria - Amgen; Celgene; Janssen |
Consulting or Advisory Role - Amgen; Amgen; Celgene; Janssen |
|
|
Employment - Bluebird Bio |
Stock and Other Ownership Interests - Bluebird Bio |
Research Funding - Bluebird Bio |
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Employment - Celgene/Bristol-Myers Squibb |
Leadership - Arcus Biosciences; Mersana |
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb |
Consulting or Advisory Role - Arcus Biosciences |
Research Funding - Celgene/Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Celgene/Bristol-Myers Squibb |
Other Relationship - Society for Immunotherapy of Cancer |
|
|
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst) |